What is the dosing of cefpodoxime (Cephalosporin antibiotic) for an uncomplicated Urinary Tract Infection (UTI)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cefpodoxime Dosing for Uncomplicated UTI

For uncomplicated urinary tract infections in adults, cefpodoxime proxetil should be dosed at 100 mg orally twice daily for 7 days, taken with food to enhance absorption. 1

Standard Dosing Regimen

  • The FDA-approved dose is 100 mg twice daily (total daily dose 200 mg) for 7 days 1
  • The medication must be taken with food to optimize absorption 1
  • This dosing applies to adults and adolescents 12 years and older 1

Evidence Supporting This Regimen

  • In a head-to-head comparison with trimethoprim-sulfamethoxazole, cefpodoxime 100 mg twice daily for 3 days achieved 98% clinical and microbiological cure rates (62/63 patients), which was equivalent to TMP-SMX 2
  • However, the FDA label specifies 7 days as the approved duration for uncomplicated UTI 1
  • Clinical trials using 100 mg twice daily for 7 days demonstrated bacteriological cure rates of 80% and clinical cure rates of 79%, comparable to other oral cephalosporins 3

Position in Treatment Algorithm

Cefpodoxime is classified as an alternative agent, not first-line therapy for uncomplicated cystitis 2

  • β-lactam agents including cefpodoxime should be reserved for situations when first-line agents (nitrofurantoin, TMP-SMX, fosfomycin) cannot be used 2
  • The rationale: β-lactams generally have inferior efficacy and more adverse effects compared to other UTI antimicrobials 2

Important Clinical Caveats

  • Cefpodoxime has lower efficacy than fluoroquinolones: In comparative studies, amoxicillin-clavulanate (another β-lactam) achieved only 58% clinical cure versus 77% with ciprofloxacin at 4-month follow-up 2
  • The small sample size (63 patients) in the key cefpodoxime study limits statistical power to detect differences 2
  • Side effects were minimal and not different from comparator agents (1.6% adverse event rate) 2

Dose Adjustments

  • Severe renal impairment (CrCl <30 mL/min): Increase dosing interval to every 24 hours 1
  • Hemodialysis patients: Dose 3 times per week after dialysis 1
  • Cirrhotic patients: No dose adjustment necessary 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.